Celyad SA (NASDAQ:CYAD) hit a new 52-week high on Monday . The company traded as high as $58.79 and last traded at $58.79, with a volume of 3,182 shares changing hands. The stock had previously closed at $56.53.

Several research firms recently issued reports on CYAD. ValuEngine raised Celyad SA from a “sell” rating to a “hold” rating in a research report on Thursday, June 29th. BidaskClub lowered Celyad SA from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $49.00 price target (up previously from $35.00) on shares of Celyad SA in a research report on Friday, September 1st.

The stock’s market capitalization is $589.79 million. The stock has a 50-day moving average of $54.61 and a 200 day moving average of $54.61.

An institutional investor recently raised its position in Celyad SA stock. Victory Capital Management Inc. lifted its stake in Celyad SA (NASDAQ:CYAD) by 6.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 374,493 shares of the company’s stock after buying an additional 22,600 shares during the period. Victory Capital Management Inc. owned approximately 3.93% of Celyad SA worth $9,988,000 at the end of the most recent quarter. Institutional investors own 4.06% of the company’s stock.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/celyad-sa-cyad-sets-new-1-year-high-at-58-79/1606372.html.

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with Analyst Ratings Network's FREE daily email newsletter.